Kornimate/medical-research-clean huggingface dataset:
micafungin versus fluconazole in the treatment of invasive candidiasis and candidemia

Conditions: Invasive Candidiasis; Candidemia

Summary: to determine the efficacy and safety of micafungin (fk463) versus fluconazole (diflucan) in treating patients with invasive candidiasis or candidaemia

micafungin (a new class of antifungal drugs) is compared to fluconazole (current standard treatment) in the treatment of patients with serious fungal infections (invasive candidiasis and candidemia) to determine its efficacy and safety. patients, both male and female, aged over 16 and with confirmed disease by the doctor could be recruited and evaluated.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of candidemia and invasive candidiasis * patients could be newly diagnosed with candidiasis who received no more than 48 hours of prior systemic antifungal therapy * inpatients aged 16 and above exclusion criteria: * patients with serious invasive candidiasis whose prognoses are considered to be poor (life expectancy judged to be less than 5 days). * patients with severe complications in the liver * pregnant or lactating women * patients who have received at least 5 days of prior systemic treatment of fluconazole or echinocandin with no response. * patients who have prior antifungal infection requiring treatment with systemic antifungal agents for conditions other than candidemia and invasive candidiasis.

Keywords: micafungin fluconazole invasive candidiasis candidemia
remote assessment of oct scans for bcc detection

Conditions: Basal Cell Carcinoma

Summary: basal cell carcinoma (bcc) is the most common form of cancer and entails approximately 80% of all cutaneous malignancies. this locally destructive neoplasm is commonly diagnosed by punch biopsy which is considered painful, causes procedural scarring and carries a small risk of infection and re-bleeding associated with invasive procedures. moreover, awaiting the results of the subsequent histopathological examination causes treatment delay and can be stressful for the patient. the drawbacks of biopsy could be overcome by optical coherence tomography (oct), a non-invasive diagnostic modality that may replace biopsy in up to 66% of patients. however, oct assessors are scarce which hinders the implementation of oct. this problem may be addressed by teledermatology in which remote oct assessment by an assessor facilitates simultaneous assessment for multiple clinics. remote oct assessment withholds the oct assessor from visually inspecting the lesion. but the effect of visual inspection on the diagnostic accuracy remains unknown and the question arises whether visual inspection is necessary for accurate oct assessment. in this diagnostic case-control study we will determine whether distant oct assessment without visual information on the lesion is non-inferior to distant oct assessment with clinical and dermoscopic photographs (cdp-oct).


Eligibility criteria:
inclusion criteria: * 18+ years of age * underwent oct scan and punch biopsy for lesions suspect for bcc exclusion criteria: * unable to sign informed consent

Keywords: basal cell carcinoma optical coherence tomography imaging non-melanoma skin cancer
phase ii trial to modulate intermediate endpoint biomarkers in former and current smokers

Conditions: Lung Diseases; Lung Cancer, Protection Against

Summary: the purpose of this study is to find out if an investigational combination drug called lovaza (made with fish oils)+curcumin c3 complex (made from a root called curcumin) can help reduce the size of lung nodules. researchers also want to find out if the combination of lovaza+curcumin c3 complex is safe and tolerable.


Eligibility criteria:
inclusion criteria: * male or female, 55 years of age or older * former smokers and current enrolled in ldct lung cancer screening or those who are detected using a regular ct, and have lung-rads 3 category lesion(s), that would get a 6 month f/u ldct or regular ct based on lung-rads recommendations or former and current smokers enrolled in ldct lung cancer screening, or regular ct and have lung-rads 2 category lesions with part-solid or non-solid lung nodule ≥4mm mean diameter detected during screening ldct or regular ct scans * history of cigarette smoking with ≥ 20 pack years * all current smokers should accept to receive smoking cessation * eastern cooperative oncology group (ecog) performance status of less than or equal to 1 * able to swallow study pills * able to undergo ct * not allergic to components of study agents * willing to discontinue current vitamin/mineral supplement use containing components of study agents. a standard multivitamin supplement provided for the study * willing to comply with proposed visit and treatment schedule * able to understand and willing to sign a written informed consent document * participants must have normal organ and marrow function * willing to use contraception during the intervention period of 6 months (males and females) * not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period.. exclusion criteria: * invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years * inability to undergo ct * newly diagnosed nodule meeting lung-rads 4 criteria * have taken doxycycline or tetracycline less than or equal to 2 weeks * females- pregnant or lactating (throughout the duration of intervention of 6 months) * unwilling to use effective form of birth control (males and females) (throughout the duration of intervention of 6 months).

Keywords: lung rads 3 lung nodule lung cancer risk chemoprevention
antioxidant effect of ozonated vegetable oil and vitamins in moderately active subjects

Conditions: Oxidative Stress; Inflammation

Summary: the purpose of this pilot study is to evaluate the antioxidant effect of a nutraceutical formulation based on vegetable oil and vitamin complex (vitamin k2 and vitamin b9) in subjects with the same level of physical activity (laf 1.70-1.99, normally active or moderately active).

study design: the pilot study will enroll 20 subjects with physical activity level laf 1.70-1.99 (normally active or moderately active). the 20 subjects will be divided into two groups of 10 subjects following randomization. the first group will take the dietary supplement (three capsules per day) for 60 days, while the second group will take a placebo (three capsules per day) for 60 days. during the treatment period (60 days), the two groups will undergo follow-ups at days 0, 15, 30 and 60 within which clinical and hematochemical examinations will be conducted. at the end of the 60 days, after the wash-out period (two weeks), as per the cross-over design the group previously taking the dietary supplement will be on placebo (three capsules per day) for 60 days, while the group previously taking placebo will take the dietary supplement (three capsules per day) for 60 days. again, follow-ups will be at 0, 15, 30 and 60 days.

Eligibility criteria:
inclusion criteria: * subjects of both sexes; * aged between 18 and 60 years, naïve to taking antioxidant supplements; * absent of chronic diseases and current therapies; * willing and able to understand and sign an informed consent; * willing to follow a dietary pattern developed according to the larn (reference intake levels of nutrients and energy for the italian population) guidelines that establish reference intake levels for average energy requirement (ar) and macronutrients (carbohydrates, lipids and protein) for the italian adult population \[larn tables\*\]; * hematobiochemical examinations in normal range: blood count, lipid status, renal and liver function, inflammatory status (tnfα, c-reactive protein, esr), glycemic profile (fasting blood glucose, hba1c, insulinemia, homa index); * bmi in the normal range (18-24.99); * physical activity level laf 1.70-1.99 (normally active or moderately active) exclusion criteria: * chronic diseases (chronic renal failure, chronic hepatocellular failure, autoimmune diseases, chronic inflammatory bowel disease, diabetes mellitus, end-stage neoplasms, symptomatic chronic ischemic heart disease) * severe hypertension; * high-grade hypercholesterolemia; * age \< 18 years; * poor compliance; * intake of dietary supplements containing antioxidants; * untreated hypothyroidism; * pregnant and lactating women; * underweight subjects (bmi ≤18.49); * overweight subjects (25≤ bmi ≤30); * subjects with obesity (bmi ≥30); * subjects with different levels of physical activity: very active (laf 2.00-2.40) and sedentary (laf 1.40-1.69).

Keywords: ozonated sunflower oil antioxidant inflammation
gut peptides and intestinal permeability in celiac disease and irritable bowel syndrome

Conditions: Celiac Disease; Irritable Bowel Syndrome

Summary: it is well known that the intestinal barrier is altered in celiac disease (cd), an autoimmune disease that develops in genetically predisposed subjects exposed to ingestion of wheat gliadin and of related prolamines of barley and rye. more recently, defective epithelial barrier has been implicated in the pathogenesis of other conditions such as irritable bowel syndrome (ibs). at present ibs is still considered a functional condition although low-grade inflammation has been associated with its manifestation, particularly that following infection. different substances have been implicated in the (dis)regulation of intestinal barrier, among them zonulin seems to play a key role. other gastrointestinal peptides are gpl-2, ghrelin, and epidermal growth factor (egf). in order to shed light on the hormonal regulation of intestinal barrier function in celiac patients before undergoing a gluten free diet and possible differences with those of ibs patients, in the present study the investigators will apply the non-invasive lactulose/mannitol permeability test toward the evaluation of intestinal damage. the pattern of intestinal permeability and the gi peptides concentration will be compared in celiac patients, ibs patients and healthy controls.


Eligibility criteria:
inclusion criteria of celiac disease patients: * diagnosis of cd was based on the detection of iga antiendomysial and iga antitissue transglutaminase antibodies in serum * diagnosis must be confirmed by a small intestinal biopsy obtained at the time of gastrointestinal endoscopy. * all patients must show marsh 3 grade villous atrophy at the time of the diagnosis. inclusion criteria of ibs patients. * subjects suffering from irritable bowel syndrome according to the rome iii criteria. * availability of at least one gi imaging study during the last five years (colonoscopy, sigmoidoscopy, abdominal ultrasound, barium enema) exclusion criteria for both the above groups: * none were taking anti-inflammatory drugs (including mast cell stabilisers, histamine antagonists, anticholinergics, anti-diarrhoea medication, probiotics, immunosuppressants and steroids) * presence of organic syndrome, including food allergy, atopy and severe clinical depression or anxiety. * abnormal laboratory data or thyroid function * major abdominal surgery healthy subjects will be recruited in the administrative staff of the institute after thorough exclusion of gi symptoms.

Keywords: celiac disease ibs intestinal barrier intestinal permeability gi peptides
low cost biological lung volume reduction therapy for advanced emphysema

Conditions: Pulmonary Emphysema

Summary: the clinical utility of bronchoscopic methods for achieving lung volume reduction has been evaluated in patients with advanced emphysema because these procedures are uniformly safer than surgical volume reduction. these include one-way valves, or bronchial occlusive devices to collapse emphysematous regions of lung and bronchial fenestration with bypass stents to improve expiratory flow, wire coils implants that compress the airway and thermal vapor ablation that causes an acute injury with subsequent fibrosis and reductions in volume.

biologic lung volume reduction (biolvr): it is a novel endobronchial approach, which uses a biological agents aiming to reduce lung volume by blocking off the most emphysematous areas with a rapidly polymerizing sealant. the mechanism of action involves resorption atelectasis from airway occlusion, subsequent airspace inflammation, and then remodeling. this remodeling will lead to scarring that induces contraction of lung parenchyma and functional volume reduction can be expected within 6-8 weeks. biological lung volume reduction occurs independent of the presence or absence of collateral ventilation.

Eligibility criteria:
inclusion criteria: 1. emphysema determined by hrct of the chest with: * .persistent symptoms (i.e. a baseline modified medical research council dyspnea (mrc) score of \>2 despite medical therapy). * fev1 /fvc \< 70% and fev1 20%-50 % (sever and very sever airflow limitation according to gold 2013). * hyperinflation (total lung capacity (tlc) \> 110% pred and residual volume/total lung capacity (rv/tlc) \> 120% pred. 2. patients not candidate for or had refused lung volume reduction surgery. 3. age \> 40 yrs. exclusion criteria: 1. airflow limitation with fev1 \< 20%. 2. dlco \< 20%. 3. current smoker. 4. patients not candidate for fob.
sensory motor arousal regulation treatment (smart) study

Conditions: PTSD; Post-traumatic Stress Disorder

Summary: this study will investigate whether a movement and body-based treatment can benefit adults with post-traumatic stress disorder (ptsd). the treatment is called sensory motor arousal regulation treatment, or "smart", and study participation involves 8 sessions of smart, as well as pre-treatment, post-treatment, and 3-month follow-up assessments.

this study will investigate the use of smart (sensory motor arousal regulation treatment) with adults experiencing symptoms related to ptsd (post-traumatic stress disorder). in addition to the more well-known symptoms of ptsd (e.g., intrusive memories, avoidance, hypervigilance, and emotion dysregulation), chronic traumatic stress seems to overwhelm the brain's capacity to make sense of sensory information, affecting how traumatized people experience their own bodies and their surroundings. smart builds on the sensory integration theory of intentionally engaging the senses via movement, touch, body awareness, and balance. the smart protocol has been used effectively to treat children who have experienced psychological trauma, and the investigators will be investigating its use with adults. participants enrolled in the study will be randomly assigned to one of two treatment conditions - i) smart, or ii) wait list (i.e., delayed treatment). study participation will involve 8, 1-hour sessions of smart, as well as pre-treatment, post-treatment, and 3-month follow-up assessments. for those assigned to the wait list condition, the same 8 smart sessions will be offered after the 3-month follow-up assessment is complete, with no further assessment required.

Eligibility criteria:
inclusion criteria: 1. adults, aged 18-65 2. a primary diagnosis of ptsd as determined by our pre-treatment assessment 3. ability to provide informed consent 4. fluency in written and spoken english (to be able to complete assessments) exclusion criteria: 1. any implants, conditions, etc. that do not comply with 7t (tesla) fmri research safety standards (e.g., pacemaker, pregnancy/possible pregnancy) 2. history of significant head injury/lengthy loss of consciousness (e.g., a glasgow coma scale score \< 15 at the time of incident as assessed retrospectively by participant) 3. significant untreated medical illness 4. history of neurological or neurodevelopmental disorder 5. history of any pervasive developmental disorder 6. lifetime bipolar or psychotic disorder 7. alcohol/substance abuse or dependence within the last 3 months 8. extensive narcotic use (e.g., fentanyl, oxycodone, etc.) 9. anyone who would not be suitable for short-term treatment (as determined by our pre-treatment assessment) 10. suicide attempt in last 6 months

Keywords: ptsd post-traumatic stress disorder body-based trauma therapy movement-based trauma therapy sensory-motor
the biological rhythm of human metabolite

Conditions: Rhythm Nodal; Metabolism and Nutrition Disorder; Metabolism Disorder, Lipid

Summary: the circadian regulation in mammals have been known for a long time. a special group of clock genes, organized in feedback loops, are responsible for the circadian regulation in both the scn and peripheral organs. the central clock is mainly entrained by the light-dark cycle, while the peripheral ones in organs such as liver and intestine, are more influenced by the feeding-fasting cycles. the coordination of central and peripheral clocks is thought to be essential in the maintenance of physiological homeostasis.this study aim to investigate the association between biological rhythm and metabolism.


Eligibility criteria:
inclusion criteria: * male or female； * aged of 18 to 30 years old; exclusion criteria: * presence of pituitary/hypothalamic disorders, polycystic ovarian syndrome， thyroid disorders, hypertension, malignant tumor, cardiac insufficiency，hepatic or renal insufficiency, gastrointestinal disorders and acute infection; * receiving psychotropic or hormonal medications including hormonal contraception and hormone therapies; * taking lipid-lowering agents or hypoglycemic agents and other drugs that known to influence cardiovascular health; * pregnancy or lactation women; * obviously poor compliance.

Keywords: biological rhythm metabolism hormone lipid bile acids obesity
optimization of fmri for the study of basal ganglia activation in parkinson's disease

Conditions: Parkinson's Disease

Summary: functional magnetic resonance imaging (fmri) is a non-invasive imaging technique assessing neuronal activations during motor or cognitive tasks. the mri sequences used are currently optimized for the study of cortex activations, particularly concerning the echo time (te).very few studies are interested in optimizing the fmri for the study of the basal ganglia, structure implicated in many neurological diseases such as parkinson's disease. the t2 \* is a tissue parameter dependent of iron content, which differs with brain structures and probably also with age and in case of neurodegenerative disease. optimal te s should correspond to the t2 \* of studied brain structure the primary purpose is to optimize the fmri by a quantitative measurement of the t2\* in the cortex and the basal ganglia using mri. the secondary purpose is to study the effect of age and parkinson's disease on t2\*.

80 subjects (40 pd patients and 40 paired healthy volunteers (on sex and age)) aged 40-80 years will be included. pd patients will be recruited in the department of neurology of chu of clermont-ferrand. healthy volunteers will be selected in clinical trial database. this study will consist of one visit (at j0) during which subjects will undergo a mri (a single acquisition of 40 minutes approximately). pd patients will be further questioned on their disease and will benefit from a neurological examination

Eligibility criteria:
inclusion criteria: * for patients : * patients with idiopathic parkinson's disease according to ukpdsbb criterias * men or women aged between 40 to 80 years * not treated with deep brain stimulation for healthy subjects - men or women aged between 40 to 80 years exclusion criteria: for patients * dementia (mms\<24) * contraindication to mri. * under guardianship * in excluding period for another study for healthy subjects * antecedent of neurodegenerative diseases or psychiatric diseases * contraindication to mri * under guardianship * in excluding period for another study

Keywords: functional magnetic resonance imaging t2* cortex and basal ganglia parkinson's disease
nac supplementation and skeletal muscle performance

Conditions: Skeletal Muscle Damage; Skeletal Muscle Performance; Intgracellular Signaling in Skeletal Muscle; Inflammatory Status

Summary: in this investigation the investigators utilized nac administration to foster gsh availability during an 8-day period following eccentric exercise-induced muscle damage in order to test our hypotheses: i) antioxidant supplementation does not disturb performance and adaptations induced by exercise-induced muscle injury and ii) redox status perturbations in skeletal muscle are pivotal for the regulation of muscle' inflammatory response and repair.

the major thiol-disulfide couple of reduced (gsh) and oxidized glutathione (gssg) is a key-regulator of major transcriptional pathways regulating aseptic inflammation and recovery of skeletal muscle following aseptic injury. antioxidant supplementation may hamper exercise-induced cellular adaptations. our objective was to examine how thiol-based antioxidant supplementation affects skeletal muscle's performance and redox-sensitive signalling during the inflammatory and repair phases associated with exercise-induced micro-trauma.in a double-blind, counterbalanced design, 12 men received placebo (pla) or n-acetylcysteine (nac, 20 mg/kg/day) following muscle-damaging exercise (300 eccentric contractions). in each trial, muscle performance was measured at baseline, post-exercise, 2h post-exercise and daily for 8 consecutive days. muscle biopsies from vastus lateralis and blood samples were collected pre-exercise and 2h, 2d, and 8d post-exercise.

Eligibility criteria:
inclusion criteria: a) recreationally trained as evidenced by their maximal oxygen consumption levels (vo2max \>45 ml/kg/min), b) were engaged in systematic exercise at least three times/week for ≥12 months), c) non-smokers, d) abstained from any vigorous physical activity during the study, e)abstained from consumption of caffeine, alcohol, performance-enhancing or antioxidant supplements, and medications during the study. exclusion criteria: a) a known nac intolerance or allergy, b) a recent febrile illness, c) history of muscle lesion, d) lower limb trauma

Keywords: aseptic inflammation skeletal muscle function exercise
international study of biofield therapy

Conditions: Pain; Depression, Anxiety; Dizziness; Signs and Symptoms

Summary: participants from 14 different countries received a single session of biofield therapy (okada purifying therapy) lasting 30 minutes or longer from the volunteer practitioners. before and after the therapy, they reported the severity of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. the team compared the effectiveness/safety of biofield therapy between countries and analyzed the factors associated with the outcomes.

participants aged 16 or older from 14 different countries (japan, usa, argentina, brazil, chile, mexico, peru, taiwan, thai, south korea, belgium, france, portugal, and spain) received a single session of biofield therapy (okada purifying therapy) lasting 30 minutes or longer from the volunteer practitioners in their country of residence. before and after the intervention, they reported each severity level of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. the team compared the improvement/exacerbation rate of a single session of biofield therapy between the countries, and examined the adjusted odds ratio of the variables associated with the changes in each category of symptoms in a real-world setting.

Eligibility criteria:
inclusion criteria: 1. individuals who agreed to receive a single session of biofield therapy for 30 minutes or longer from the volunteer investigators. 2. individuals who were able to self-evaluate the change of their symptoms. 3. individuals who were competent to answer the questionnaires. 4. individuals who were aged 16 or older. exclusion criteria: * no specific exclusion criteria

Keywords: biofield therapy ethnic differences okada purifying therapy effectiveness safety